Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease  by Kennedy, Edward M. et al.
Suppression of hepatitis B virus DNA accumulation in chronically
infected cells using a bacterial CRISPR/Cas RNA-guided
DNA endonuclease
Edward M. Kennedy a,1, Leda C. Bassit b,1, Henrik Mueller c, Anand V.R. Kornepati a,
Hal P. Bogerd a, Ting Nie b, Payel Chatterjee b, Hassan Javanbakht c,
Raymond F. Schinazi b,n, Bryan R. Cullen a,nn
a Department of Molecular Genetics & Microbiology and Center for Virology, Duke University Medical Center, Durham, NC, United States
b Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta,
GA, United States
c Infectious Diseases, F. Hoffmann-LaRoche, Inc., Basel, Switzerland
a r t i c l e i n f o
Article history:
Received 2 October 2014
Returned to author for revisions
14 November 2014
Accepted 1 December 2014
Available online 29 December 2014
Keywords:
HBV
cccDNA
CRISPR/Cas
Antiviral
DNA editing
Lentiviral vector
a b s t r a c t
Hepatitis B virus (HBV) remains a major human pathogen, with over 240 million individuals suffering
from chronic HBV infections. These can persist for decades due to the lack of therapies that can
effectively target the stable viral covalently closed circular (ccc) DNA molecules present in infected
hepatocytes. Using lentiviral transduction of a bacterial Cas9 gene and single guide RNAs (sgRNAs)
speciﬁc for HBV, we observed effective inhibition of HBV DNA production in in vitro models of both
chronic and de novo HBV infection. Cas9/sgRNA combinations speciﬁc for HBV reduced total viral DNA
levels by up to 1000-fold and HBV cccDNA levels by up to 10-fold and also mutationally inactivated
the majority of the residual viral DNA. Together, these data provide proof of principle for the hypothesis
that CRISPR/Cas systems have the potential to serve as effective tools for the depletion of the cccDNA
pool in chronically HBV infected individuals.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Hepatitis B virus (HBV) remains an important human pathogen
despite the existence of a highly effective vaccine. Particularly in
resource-limited contexts, vaccination rates remain well under
100% and vaccination at birth of infants born to HBV positive
mothers is not fully protective against vertical transmission
(Komatsu, 2014). Moreover, it is estimated that over 240 million
individuals, 4% of the world population, remain chronically
infected with HBV and are therefore at high risk for cirrhosis
and hepatocellular carcinoma (HCC), leading to 800,000 deaths
per year that are directly linked to HBV infection (Komatsu, 2014).
Treatment of HBV primarily relies on the use of nucleoside
analog chain terminators, such as lamivudine (3TC), tenofovir
disoproxil fumarate (TDF) and entecavir (ETV), which act as potent
inhibitors of the HBV reverse transcriptase (RT). However, while
these drugs can clearly slow the progression of HBV-induced
disease, including both cirrhosis and HCC, they do not lead to a
full elimination of this viral infection. This is due to the very high
stability of an episomal DNA intermediate in the HBV replication
cycle, called covalently closed circular DNA (cccDNA), that persists
in the nuclei of infected hepatocytes and serves as the template for
viral mRNA and pre-genomic RNA synthesis (Werle-Lapostolle
et al., 2004). While RT inhibitors can prevent the de novo HBV
infection of additional hepatocytes, the cells infected at the time of
treatment initiation remain infected and only gradually decrease
in number due to cell turnover. Therefore, in order to effectively
clear an HBV infection and produce full remission, the viral
cccDNA intermediates need to be destroyed. This goal has now
become feasible due to the development of programmable RNA-
guided DNA endonucleases derived from the Type II bacterial CRISPR
(clustered regularly interspaced short palindromic repeats)/Cas
mechanism of bacterial adaptive innate antiviral immunity (Hsu
et al., 2014).
Type II CRISPR/Cas systems rely on a single effector protein,
called CRISPR-associated protein 9 (Cas9), that is normally guided
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to a speciﬁc DNA sequence by two small RNA molecules called the
tracrRNA and the crRNA (Barrangou and Marrafﬁni, 2014; Hsu
et al., 2014). The demonstration that the tracrRNA and crRNA could
be combined into a single guide RNA (sgRNA) (Cong et al., 2013;
Mali et al., 2013) enhanced the feasibility of using CRISPR/Cas
systems as effective gene editing tools in eukaryotic cells. Pre-
viously, most research has focused on using the Cas9 protein from
Streptococcus pyogenes (Spy), which uses a 20-nt guide sequence to
target complimentary DNA sequences that are ﬂanked 30 by a so-
called protospacer adjacent motif (PAM), with the sequence
50-NGG-30. The PAM, which forms an invariant part of every Spy
Cas9-speciﬁc DNA target, is directly recognized by the Cas9 protein
and initiates DNA targeting guided by the sgRNA (Barrangou and
Marrafﬁni, 2014; Cong et al., 2013; Hsu et al., 2014; Mali et al.,
2013). Using transfection or lentiviral vector transduction, it is
possible to induce cleavage of speciﬁc DNA sequences present in a
mammalian genome by expression of Spy Cas9 and an sgRNA
molecule transcribed by an RNA polymerase III promoter (Cong
et al., 2013; Mali et al., 2013). Gene inactivation using this system
is both efﬁcient and speciﬁc, and Spy Cas9 has in fact been used for
not only high throughput genetic screens in human cells in culture
(Shalem et al., 2014; Wang et al., 2014; Zhou et al., 2014) but also
for the generation of gene knockouts in several species, including
mice and even monkeys (Yang et al., 2013). We therefore reasoned
that the Spy Cas9 protein, in combination with sgRNAs designed to
select a target present on the HBV cccDNA, might represent a
powerful method to cleave and eradicate HBV cccDNAs. In the
present study, we demonstrate that lentiviral vectors encoding Spy
Cas9/sgRNA combinations targeted to the HBV reverse transcrip-
tase (RT), surface antigen (Ag) or core protein genes are all able to
effectively repress viral DNA production, including cccDNA accu-
mulation, in chronically HBV infected cells and also inhibit de novo
HBV infection. Moreover, these Spy Cas9/sgRNA combinations
showed additive inhibition of HBV DNA accumulation when used
in combination with known pharmacological inhibitors of the HBV
RT enzyme. These experiments provide evidence in support of the
hypothesis that HBV-speciﬁc Spy Cas9/sgRNA combinations, when
delivered to HBV-infected hepatocytes in vivo by viral transduc-
tion, might provide a novel and effective approach to facilitate the
elimination of HBV in chronically infected individuals.
Results
To target the HBV genome (subtype AYW) for elimination in
cell culture, we ﬁrst designed three sgRNAs speciﬁc for Spy Cas9
targeting the viral open reading frames (ORFs) encoding HBV
surface Ag, core, and/or RT. For the HBV structural proteins surface
Ag and core, N-terminal targets were selected to induce frame-
shift mutagenesis. The surface Ag speciﬁc sgRNA was also pre-
dicted to cleave the RT gene (Fig.1 A). RT was also targeted in the
highly conserved “YMDD” motif required for enzyme catalysis
(Fig. 1A) using an sgRNA predicted to also cleave near the end of
the surface Ag ORF. To verify effective sgRNA function, we
employed a previously described (Kennedy et al., 2014) indicator
assay based on co-transfection of Spy Cas9 and sgRNA expression
plasmids, along with a cognate indicator plasmid, into human
293 T cells. This assay quantitatively measures sgRNA efﬁcacy by
monitoring the ﬁreﬂy luciferase (FLuc) activity or steady state
expression level of an HIV-1 Rev–sgRNA target–FLuc fusion pro-
tein; high cleavage activity results in a substantial knockdown of
both. As shown in Figs. 1B and C, all three sgRNAs induced an
effective and speciﬁc knockdown of Fluc expression, as measured
by dual luciferase assay, and Rev fusion protein expression, as
measured by Western blot analysis, respectively. To directly test
these three sgRNA constructs in relevant HBV cell-culture models,
we next shuttled them into a lentiviral Cas9/sgRNA expression
vector (Shalem et al., 2014) capable of efﬁcient transduction of the
cell lines HepAD38 and HepaRG (Fig. S1).
Suppression of HBV replication by Cas9/sgRNA combinations speciﬁc
for the HBV RT, surface Ag and core genes
In the HepAD38 cell line, transcription initiation of an inte-
grated HBV linear DNA genome is tightly regulated by a Tet
repressed promoter (Ladner et al., 1997). In the absence of Tet in
the culture medium, the system mimics HBV replication by
transcribing HBV mRNAs and pre-genomic RNA, leading to the
initiation of a robust HBV replication cycle, including the synthesis
of substantial levels of HBV cccDNA, and the release of DNA-
containing viral particles into the supernatant medium. Conse-
quently, this cell line represents an excellent model to test
suppression of HBV replication and cccDNA synthesis by Spy
Cas9 loaded with sgRNAs speciﬁc for HBV DNA targets. Therefore,
we tested the ability of this system to suppress HBV replication by
transducing HepAD38 cells with lentiviral vectors encoding HBV-
speciﬁc Cas9/sgRNA combinations. HBV transcription was acti-
vated 48 h prior to transduction by removal of Tet from the
medium to ensure that an active HBV replication cycle was in
progress prior to Cas9/sgRNA expression. Subsequently, Tet was
added back to the medium again, repressing the chromosomal
HBV locus, to ensure that cccDNA was the primary source of viral
transcription. The lentiviral vectors used also encode a puromycin
resistance gene (Shalem et al., 2014), thus permitting selection of
the transduced cells. As a positive control for HBV gene expression,
HepAD38 cells were also transduced with a non-speciﬁc (N.S.)
sgRNA construct that does not target any HBV sequence. As a
control for maximally repressed HBV expression, HepAD38 cells
were also tested in the continuous presence of Tet, which in the
HepAD38 cells blocks HBV transcription (Ladner et al., 1997). After
transduction and selection, all three sgRNAs reduced HBV DNA
levels inside cells by 10 to 125-fold and in the supernatant
media by 100-fold to 800-fold, as measured by real-time
PCR (Fig. 2A). Even more impressively, the RT sgRNA suppressed
HBV DNA replication to the same extent as Tet addition, which
essentially entirely blocks virus replication.
Suppression of cccDNA formation by HBV speciﬁc Cas9/sgRNA
combinations
To test the capacity of HBV-speciﬁc Cas9/sgRNA combinations
to eliminate cccDNA accumulation, transduced HepAD38 cells
were also analyzed for the level of cccDNA accumulation by real-
time PCR after 14 days in culture using previously described
cccDNA-speciﬁc primers (Chen et al., 2004). Remarkably, the
HBV RT-speciﬁc sgRNA suppressed cccDNA formation by 10-
fold, while the surface Ag and core-speciﬁc sgRNAs repressed
cccDNA levels by 4-fold (Fig. 2B). Total intracellular HBV DNA
accumulation was reduced by 8-fold by the HBV surface Ag and
core-speciﬁc sgRNAs, and were repressed by 80-fold by the RT
speciﬁc sgRNA (Fig. 2B). Impressively, the HBV RT speciﬁc sgRNA
was therefore able to reduce HBV cccDNA formation by 90% and
total HBV intracellular DNA accumulation by 99%.
HBV-speciﬁc Cas9/sgRNA combinations reduce HBV surface Ag
secretion
In HepAD38 cells, analysis of the level of HBV surface Ag (HBsAg)
and “e” Ag (HBeAg) secretion represents a useful assay for screening
for antivirals that inhibit HBV replication and/or viral gene expres-
sion. To determine if HBV-speciﬁc Cas9/sgRNA combinations can
suppress secretion of these viral antigens, we performed an ELISA
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assay using the supernatant media of transduced HepAD38
cells harvested after 12 days in culture. Low levels of secreted
HBsAg were observed in the supernatant of HepAD38 cells trans-
duced with HBV-speciﬁc sgRNAs targeting the RT, surface and core
genes but not the N.S. sgRNA. Indeed, the surface Ag-speciﬁc
sgRNA suppressed HBsAg production to nearly undetectable levels
(Fig. 2C), possibly consistent with the mutational inactivation of this
viral gene due to editing by the cognate Cas9/sgRNA combination.
We also observed a statistically signiﬁcant reduction in HBeAg
secretion in the cells transduced with the RT speciﬁc sgRNA,
indicating perhaps a global reduction in cccDNA in this case
(Fig. 2D). In contrast, we did not observe a signiﬁcant reduction in
HBeAg for the Core and Surface sgRNAs, and this likely results from
this protein’s secretion and exceptional stability. In contrast to the
HBsAg ORF, it should be noted that none of the sgRNAs employed
directly target this viral ORF for mutagenic inactivation.
Mutational inactivation of HBV by Cas9/sgRNA combinations
While the observed depletion of total HBV DNA and cccDNA
accumulation was extensive (Fig. 2A and B), we were also curious
as to the mutational status of the residual viral DNA as Cas9
cleavage of chromosomal targets usually results in the introduc-
tion of small sequence insertions or deletions (indels) (Shalem
et al., 2014). For this purpose, we focused on HepAD38 cells
transduced with the sgRNA speciﬁc for the active site YMDD motif
of the HBV RT gene (Fig.1A). We harvested total DNA from the
HepAD38 cells transduced with the RT-speciﬁc Cas9/sgRNA com-
bination that we had previously shown effectively knocked down
viral DNA levels (Figs. 2A and B) and subjected the DNA to PCR
ampliﬁcation using HBV RT speciﬁc primers followed by cloning
and sequencing of the resultant HBV DNA fragments. Seventy-
three deletion mutations located at or immediately adjacent to the
predicted Cas9 cleavage site present 3 bp 50 to the target DNA PAM
sequence were recovered, and we also detected ﬁve insertion
mutations at this same location in the HBV genome (Fig. 3). Of the
103 recovered viral sequences, 78 (76%) were found to be mutated
and, interestingly, the bulk of the amplicons recovered were
predicted to be lethally mutagenized; even an in-frame insertion
or deletion would be highly detrimental as these residues are
required for HBV RT function and therefore highly conserved. In
conclusion, expression of a Cas9/sgRNA combination speciﬁc for
the HBV RT gene not only dramatically reduced viral DNA levels, as
expected (Fig. 2A and B), but also mutationally inactivated the
majority of the low level of residual viral DNA.
Targeting HBV with Cas9/sgRNA combinations reduced antigen
secretion and viral replication and leads to cccDNA degradation in
infected HepaRG cells
HepAD38 cells are an excellent model of post-entry chronic
infection, but to test whether Cas9/sgRNA combinations speciﬁc
Fig. 1. HBV targeting strategy and sgRNA optimization. To target HBV DNA intermediates in infected cells, we designed sgRNAs speciﬁc for the HBV surface Ag, core, and RT
ORFs, as depicted in panel A. To assess efﬁcacy, fusion protein-based indicator plasmids, which encode an amino-terminal HIV-1 Rev-derived epitope tag, an in-frame HBV-
derived target, and a carboxy-terminal FLuc indicator gene, were employed. As shown in panel B, all three sgRNA candidates effectively inhibited FLuc expression from their
cognate reporter plasmid in co-transfected 293 T cells when compared to a control, non-speciﬁc (N.S.) sgRNA. In panel C, expression of the same fusion protein was probed
by Western blot using a previously described α-Rev rabbit polyclonal antiserum (Kennedy et al., 2014). Co-expression of Cas9 was conﬁrmed using an antibody speciﬁc for
the FLAG epitope tag present on this protein. When the reporter was cognate for the sgRNA, a marked reduction of the expression level of the fusion protein target could be
observed, conﬁrming the speciﬁcity and efﬁcacy of each sgRNA tested.
E.M. Kennedy et al. / Virology 476 (2015) 196–205198
for HBV are also capable of inhibiting de novo infection we
employed a second cell culture model, HepaRG cells. These cells
are permissive for infection with live HBV virus subsequent to
differentiation (Gripon et al., 2002) and are an excellent comple-
ment to the HepAD38 system, which models the late stage of the
HBV lifecycle (Ladner et al., 1997). To assess the effect of HBV-
speciﬁc sgRNAs on HBV replication in HepaRG cells, we transduced
these cells with the lentiviral constructs described above, expres-
sing HBV RT, surface Ag, core, or control N.S. sgRNAs. After
selection for puromycin resistance and differentiation, these cell
lines were infected with HBV at a high MOI of 30 and the
antiviral effects of the sgRNAs evaluated (Fig. 4). Both HBsAg and
HBeAg) secretion was reduced by up to 80% by 17 days after
infection in the presence of HBV-speciﬁc sgRNAs (Fig. 4A and B)
and this reduction was highly signiﬁcant. This effect could be due
either to a direct effect of the sgRNA on the expression of the
speciﬁc viral gene or, perhaps more likely, a global reduction in
cccDNA production and HBV transcription. To further investigate
the impact and speciﬁcity of the panel of HBV-speciﬁc Cas9/sgRNA
combinations, we isolated DNA from the supernatant media and
cell lysates of the HepaRG RT, surface Ag, core, and N.S. sgRNA-
expressing cells following infection with HBV in the presence or
absence of ETV treatment (see schematic in Fig. 4C). ETV, a
nucleoside analogue, has been shown to reduce HBV DNA levels
by inhibiting reverse transcription, but does not directly affect
cccDNA stability in HepaRG cells (Lucifora et al., 2014). Moreover,
in the context ETV treatment and viral inhibition, Cas9/sgRNAs
might represent an effective means to eliminate cccDNA from the
treated and suppressed cells. We therefore isolated total DNA from
ETV-treated and untreated HepaRG cells and used these for qPCR
analysis of total HBV DNA levels present either in viral particles
released into the supernatant media (Fig. 4D) or present intracel-
lularly (Fig. 4F). As expected, in the presence of ETV, HBV DNA was
greatly reduced both in the supernatant (by 96%) and intracel-
lularly (by 80%). In addition, all three sgRNAs targeting the HBV
genome also induced a reduction in HBV total DNA levels in the
supernatant media and inside infected cells, arguing that not only
are HBe- and HBs-antigen gene expression speciﬁcally inhibited,
but that HBV replication is also globally reduced by the HBV
speciﬁc Cas9/sgRNA combinations tested. To further investigate if
this reduction is due to degradation of the viral genome in the
infected cells, intracellular DNA was subjected to qPCR using
primers that speciﬁcally amplify cccDNA. All three sgRNAs led to
reductions in cccDNA levels in infected HepaRG cells (up to 67%)
(Fig. 4E), providing evidence that the Cas9/sgRNA combinations
directly act on viral cccDNA intermediates. As expected, ETV
Fig. 2. Suppression HBV replication by HBV-speciﬁc Cas9/sgRNA combinations. HBV replication was ﬁrst induced in the HepAD38 cells by culture in the absence of Tet for
48 h. Then, the cells were transduced with lentiviral vectors encoding Spy Cas9/sgRNA combinations speciﬁc for the HBV RT, surface Ag or core ORFs, and puromycin selected.
HepAD38 cells were also maintained in Tetþ media as a negative control. The HepAD38 cells and supernatant media were harvested and total HBV DNA (A) and intracellular
HBV DNA or cccDNA (B) quantiﬁed by qPCR after 10 or 14 days in culture, respectively. (þ) indicates the sample was below the detection limit (445 cycles). All results of
qPCR assays were normalized to the N.S. sgRNA control cell line. Levels of HBsAg (C) and HBeAg (D) secreted into the culture media were measured by ELISA after 10 days in
culture. Data are displayed as the mean7SD of replicates. Statistical analyses were performed using Student’s t-test for comparison between two groups using JMP pro 10
software. A value of po0.05 (n) was considered statistically signiﬁcant. (nnn) represents po0.001.
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treatment had no effect on cccDNA levels, and the observed almost
complete inhibition of overall HBV DNA production by ETV in the
supernatant media and intracellularly (Fig. 4D and F) further
conﬁrms the high speciﬁcity of the primers used for cccDNA
detection. Overall, these data therefore suggest that HBV DNA
cleavage by Cas9/sgRNA combinations has the potential to not only
disrupt HBV replication but also viral cccDNA stability.
Enhanced inhibition of HBV DNA accumulation by antivirals in
combination with Cas9/sgRNAs
To further assess the possibility that other potent RT inhibitors
(TDF, ETV or 3TC) or a viral assembly inhibitor (HAP12) could
enhance elimination of residual virus from HBV-speciﬁc Cas/
sgRNA expressing cells, we treated HepAD38 cells at concentra-
tions that only partly inhibit HBV DNA replication in this system,
as measured by real-time PCR of secreted HBV DNA. First, we
assessed the level of viral inhibition in cells expressing Cas9 and
the control N.S. sgRNA and all inhibitors tested exhibited the
expected dose response (Fig. 5A). Remarkably, and as previously
observed (Fig. 2A), HepAD38 cells expressing the HBV RT-speciﬁc
sgRNA showed essentially complete suppression of secreted HBV
DNA accumulation and gained no added beneﬁt from the viral
replication inhibitors employed (Fig. 5B). However, with the less
effective surface Ag and core-speciﬁc sgRNAs, there was a modest
but readily detectable enhancement of the level of induced
inhibition of secreted HBV DNA in the presence of the antivirals,
as shown in Fig. 5C and D. To further conﬁrm these results, we
used a constitutively HBV-expressing cell system, HBV2.2.15 cells
(Liu et al., 2004; Sells et al., 1987). After transduction with Cas9/
sgRNA expressing lentiviral constructs and selection, we observed
that extracellular levels of HBV DNA were suppressed by 98%,
80%, and 90%, respectively, by the RT, surface Ag, and core
speciﬁc Cas9/sgRNA combinations (Table 1). Importantly, treat-
ment of these cells with 1 mM of TDF, ETV, HAP12 or 3TC
demonstrated a clear at least additive effect, leading to more
efﬁcient elimination of residual HBV DNA replication, for the less
effective surface Ag- and core-speciﬁc sgRNA in 2.2.15 cells
(Table 1). In the case of the RT-speciﬁc sgRNA, the detection of a
possibly synergistic level of inhibition was again largely prevented
by the extremely high efﬁcacy of this Cas9/sgRNA combination.
Cytotoxicity analysis
For both HepAD38 and HepaRG cells transduced with lentiviral
sgRNA/Cas9 expression vectors cytotoxicity assays were per-
formed, and no cellular toxicity was observed using two distinct
assays at late timepoints (see the Materials and methods section
and Table S1).
Fig. 3. An HBV RT-speciﬁc Cas9/sgRNA combination induces extensive mutagenesis of the residual HBV DNA. Total cellular DNA was used as a template to amplify viral DNA
sequences ﬂanking the predicted HBV RT sgRNA target site (Fig.1A). The resultant PCR fragment was then cloned and sequenced. Shown above the multiple alignments of the
recovered clones are the key RT active site residues “YMDD”, which includes two of the three aspartate residues required to chelate the Mg2þ ion required for catalysis. The
cognate sgRNA sequence is underlined and shown in red, while the Spy Cas9 PAM sequence (50-NGG-30) is shown in green. Cleavage by Spy Cas9 is expected to occur 3 base
pairs 50 of this sequence. To the right of each HBV sequence variant we list the number of times each sequence was recovered. Of the 103 sequences analyzed, 78 bore
deletions while 5 contained insertions adjacent to the predicted cleavage site.
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Discussion
Despite an effective vaccine, HBV remains a serious human
pathogen, with over 240 million infected individuals worldwide
leading to 800,000 deaths annually, primarily from cirrhosis and
HCC (Komatsu, 2014). Nucleoside inhibitors such as ETV and TDF
are effective inhibitors of the HBV RT enzyme and can prevent the
release of infectious virions from HBV infected cells, but they are
unable to cure HBV due to the remarkable stability of the viral
cccDNA intermediate, which is not a direct target for these drugs
(Lucifora et al., 2014). Recently, RNA-guided DNA endonucleases
belonging to the CRISPR/Cas family (Hsu et al., 2014) were shown
to effectively cleave and inactivate viral DNA in both HIV-1 and
HPV-infected human cells (Ebina et al., 2013; Hu et al., 2014;
Kennedy et al., 2014), and we therefore wished to test whether
Cas9/sgRNA combinations speciﬁc for the HBV DNA genome might
be able to also cleave and reduce HBV DNA levels, including levels
of cccDNA, in infected human cells in culture.
The system we have used relies on the delivery of the Spy Cas9
protein and an HBV-speciﬁc sgRNA to HBV-infected hepatoma
cells using a lentiviral vector system (Shalem et al., 2014). We
selected three distinct target sites in the HBV genome, focused on
the viral surface Ag, core and RT ORFs (Fig. 1A) and were able to
conﬁrm that all three sgRNAS were active using indicator
constructs containing cognate HBV DNA segments (Fig. 1). We
next introduced each Cas9/sgRNA combination, or a control non-
speciﬁc sgRNA, into the cell line HepaRG (Ladner et al., 1997) by
lentiviral transduction, selected transduced cells using puromycin
and then quantiﬁed the ability of the HBV DNA genome chromo-
somally integrated in these cells to support a complete viral
replication cycle. To ensure that any observed inhibition did not
reﬂect simply the mutational activation of the single integrated
HBV copy, we removed Tet, which blocks HBV transcription in
HepAD38 cells, 48 h prior to transduction resulting in the produc-
tion of readily detectable levels of unintegrated HBV DNA, includ-
ing cccDNA. Nevertheless, we observed a strong inhibition of viral
DNA accumulation upon introduction of any of the three HBV-
speciﬁc Cas9/sgRNA combinations, with the RT-speciﬁc sgRNA,
which targets the essential “YMDD” motif in the HBV RT ORF for
cleavage, being particularly effective. In fact, the RT-speciﬁc sgRNA
reduced total viral DNA released into the supernatant media, by
1000-fold and total intracellular HBV DNA levels by 100-fold,
which is comparable to the inhibitory effect seen upon retention of
Tet in the culture media (Fig. 2A). The Cas9/sgRNA combinations
used also inhibited the accumulation of cccDNA in this system,
with the RT-speciﬁc sgRNA again most effective, though the
maximal reduction in this case was 10-fold (Fig. 2B). Measure-
ment of viral surface Ag production also revealed a clear inhibition
Fig. 4. HBV-speciﬁc Cas9/sgRNA combinations can reduce both viral production and cccDNA accumulation. HepaRG cells transduced with lentiviral Cas9/sgRNA expression
vectors were infected with HBV (MOI¼30) and HBsAg-(A) and HBeAg-(B) secretion measured 4 and 17 days post-infection. Results are presented relative to non-infected
control cultures. Data are displayed as mean7SD of replicates and statistics were performed using unpaired Student’s t-test (p40.05 (n.s.); po0.001(***); po0.0001(****)).
HBV-infected, transduced HepaRG cells were treated with 1 mM ETV 5 dpi for 8 days (shown schematically in (C). On day 13, HBV DNA secretion (D), intracellular cccDNA
expression (E) and total intracellular HBV DNA (G) were measured by speciﬁc qPCR. HBV secreted DNA levels and total intracellular HBV DNA accumulation were quantiﬁed
by using an HBV-containing plasmid as the standard. Levels of cccDNA are given relative to the non-infected control culture. Data are displayed as mean7SD of replicates. N.
S., non-speciﬁc sgRNA.
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Fig. 5. Antiviral activity of TDF, ETV, HAP12, and 3TC in HepAD38 cells. HepAD38 cells transduced with lentiviral vectors expressing various Cas9/sgRNA combinations were
treated with 0.1 mM 3TC or with several concentrations (mM) of HAP12, TDF or ETV, as indicated in the y-axes. On day 7, total levels of secreted HBV DNA were measured by
real-time PCR, and are here shown as both log viral inhibition and percent inhibition of the level of HBV DNA replication seen in the positive control. All data were
normalized to untreated cells expressing Cas9 and the N.S. sgRNA. Panels A, B, C and D show results obtained using HepAD38 cells transduced with lentivectors expressing
the N.S., RT, surface Ag and core sgRNAs, respectively. Log total viral inhibition is shown in the left panel, and percent inhibition is shown in the right panel in each case. Data
are displayed as mean7SD of replicates. –Tet indicates absence of Tet in culture media; TDF, tenofovir disoproxil fumarate; ETV, entecavir; HAP12, capsid assembly effector
12; 3TC, lamivudine.
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caused by all three Cas9/sgRNA combinations, though in this case
the surface Ag-speciﬁc sgRNA was most effective, possibly due to
mutational inactivation of the surface Ag ORF due to frameshifting
(Fig. 2C). In contrast, only a modest inhibitory effect on HBeAg
secretion was observed, likely in part because no sgRNA speciﬁc
for this HBV ORF was tested.
To examine whether HBV-speciﬁc Cas9/sgRNA combinations
were indeed inducing inactivating indels at their predicted clea-
vage site in the HBV genome, as expected (Shalem et al., 2014), we
cloned and sequenced PCR-generated DNA fragments that tra-
versed the predicted cleavage site in the HepAD38 cells expressing
the highly effective RT-speciﬁc sgRNA and observed deletions or
insertions in 78 out of 103 sequenced clones. The RT-speciﬁc
sgRNA already reduced HBV DNA levels by 100–1000-fold, and it is
therefore clear that not only is very little HBV DNA present in the
cells transduced with the RT-speciﬁc Cas9/sgRNA combination but
also what little viral DNA is left has almost all been mutationally
inactivated by error-prone repair of the Cas9-induced cleavage
site.
To extend these studies to a system that supports de novo HBV
infection, we also analyzed the effect of these Cas9/sgRNA combi-
nations on HBV replication in the permissive HepaRG cell line
(Gripon et al., 2002). As may be observed in Fig. 4, we again were
able to detect a substantial inhibition in the accumulation of HBV
DNA in these cells, including cccDNA (Fig. 4E) as well as a clear,
statistically signiﬁcant reduction in both HBgAg and HBeAg
production at later time points (Fig. 4A and B). Finally, we also
tested whether expression of Cas9/sgRNA combinations would be
able to inhibit HBV replication more effectively when used
together with known inhibitors of the HBV life cycle, including
3TC, TDF, ETV and HAP-12. As shown in Fig. 5 and Table 1, we were
indeed able to observe enhanced inhibition of HBV replication by
HBV-speciﬁc Cas9/sgRNA combinations in both HepAD38 cells and
in the chronically HBV-infected cell line HBV2.2.15 (Sells et al.,
1987) in the presence of various antiviral drugs. We therefore
believe that the use of CRISPR/Cas system to directly target HBV
cccDNA in the infected liver clearly merits further testing to assess
whether there is real potential for a possible cure for chronic HBV
infections when effective Cas9/sgRNA combinations are used
together with current antiviral drugs.
While this current study used the Spy Cas9 protein, and
cognate sgRNAs, delivered by lentiviral vector transduction
(Shalem et al., 2014) we believe that future efforts should focus
on the use of adeno-associated virus (AAV) vectors, as these can
potentially be generated at very high titers, up to 1014 virion
particles per ml, and have a high degree of tropism for hepato-
cytes. However, the Spy Cas9 gene, at 4.2 kb, is too large for
incorporation into AAV vectors, as these can only accommodate
4.6 kb of DNA, which would need to include not only the Cas9
ORF but also the sgRNA, as well as the transcriptional regulatory
regions required for Cas9 mRNA and sgRNA expression and, ﬁnally,
the AAV inverted terminal repeats. However, there are several
smaller (3.2 kb) Cas9 genes known in other bacterial species of
which at least one, expressed by Neisseria meningitidis (Nme) has
been characterized (Esvelt et al., 2013). Our initial data indeed
suggest that Nme Cas9 is as effective as Spy Cas9 in inducing target
DNA cleavage and inactivation (data not shown), thus raising the
clear possibility of generating single AAV vectors able to deliver
complete, fully functional Cas9/sgRNA combinations speciﬁc for
HBV to the liver in vivo at high efﬁciency. Whether Cas9/sgRNA
combinations are entirely safe, and whether their efﬁciency can be
high enough to effectively clear the HBV cccDNA pool, are issues
that will next need to be carefully addressed in animal models of
HBV infection (Dandri and Lutgehetmann, 2014).
While this article was in preparation, Lin et al. (2014) reported
that HBV-speciﬁc Spy Cas9/sgRNA combinations were able to
cleave HBV DNA when Cas9 and HBV expression plasmids were
co-transfected into Huh7 cells. Neither HBV-infected human cells
nor HBV cccDNA levels were examined in this previous work.
Here, we substantially extend these recent ﬁndings by demon-
strating HBV DNA cleavage and suppression, including repression
of cccDNA accumulation, in both a model of chronic HBV infection
(HepAD38 cells) and during de novo infection (HepaRG cells) in
culture. These novel observations therefore provide substantial
support for the idea that bacterial CRISPR/Cas systems have the
potential to function as an effective treatment for DNA virus
infections.
Material and methods
Single guide RNA design and lentiviral vector production
Multiple sgRNAs for each HBV DNA target were screened using
a dual luciferase indicator assay, essentially as described pre-
viously (Kennedy et al., 2014). Brieﬂy, Spy Cas9/sgRNA coexpres-
sion constructs based upon pX330 (Cong et al., 2013) were co-
transfected into 293 T cells at an 8:1 ratio relative to an indicator
plasmid expressing a fusion protein consisting of an amino-
terminal HIV-1 Rev derived epitope tag, a central target region
derived from an HBV open reading frame and lastly a carboxy-
terminal ﬁreﬂy luciferase (FLuc) indicator gene. A Renilla luciferase
expression plasmid was also co-transfected as an internal control.
Transfections were analyzed at 72 h post-transfection by Promega
dual luciferase assay and Western blot for the expression of the
encoded Rev-target-Fluc fusion protein to conﬁrm the speciﬁc
knockdown of the DNA target. The HBV DNA targets for the
sgRNAs are depicted in Fig. 1A. These candidate sgRNAs were
shuttled into the LentiCRISPR lentiviral expression vector (Shalem
et al., 2014), which was produced at high titer in 293 T cells by co-
transfection, as previously described (Kennedy et al., 2014).
HBV strain AYW targets for the sgRNAs used in this work were
as follows: HBV RT (GTTCAGTTATATGGATGATG), HBV surface anti-
gen (Ag) (GCCTGTCCTCCAACTTGTCC), HBV core protein (GTACCG-
CCTCAGCTCTGTAT), and nonspeciﬁc control (N.S.) (GAAATCCTG-
CAGAAAGACCT). The initial G required for efﬁcient RNA polymer-
ase III transcription from the U6 promoter is underlined and is not
complementary to the DNA target.
To assess the mutagenic spectrum generated by Spy Cas9/
sgRNA cleavage, primers bearing unique restriction sites were
designed to anneal to HBV sequences ﬂanking the predicted
Cas9 cleavage site in the RT gene. Total HBV genomic DNA was
extracted from HepAD38 cells following transduction with the
Cas9/sgRNA combination speciﬁc for the HBV RT gene described
above, PCR ampliﬁed, cloned into pcDNA3 (Invitrogen), and Sanger
Table 1
Antiviral activity of TDF, ETV, HAP12, and 3TC in HBV2.2.15 cells. Percent inhibition
of HBV DNA release into the supernatant medium relative to untreated, HBV2.2.15
cells expressing the non-speciﬁc control sgRNA.
Compound N.S.
sgRNA
HBV RT
sgRNA
HBV surface
sgRNA
HBV core
sgRNA
Untreated 0.00 97.670.2 79.673.9 90.371.4
TDF, 1 mM 68.171.5 98.970.2 95.970.7 97.070.3
ETV, 1 mM 78.377.9 98.571.0 97.671.1 97.970.6
HAP12, 1 mM 77.575.2 97.570.7 98.070.3 97.670.1
3TC, 1 mM 61.476.2 99.170.03 96.370.1 97.170.5
N.S., non-speciﬁc, RT, reverse transcriptase.
All values represent the average7SD of an experiment performed in triplicate.
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sequenced. The recovered sequences were then aligned to the
wild-type HBV strain AYW genome.
Cell culture
The human 293 T cells employed in the reporter assays and for
lentiviral vector production were cultured in Dulbecco’s modiﬁed
Eagle medium (DMEM) including 10% fetal bovine serum (FBS) and
antibiotics. The HepAD38 cell line regulates HBV replication
through the presence or absence of Tet in the culture medium
(King and Ladner, 2000; Ladner et al., 1997). Upon removal of Tet
from the medium, HBV replicates and is secreted from these cells,
while Tet addition completely represses HBV replication. HepAD38
cells were cultured in DMEM/F12 medium (Life Technologies)
supplemented with 10% heat-inactivated FBS, 100 IU/ml penicillin,
100 mg/ml streptomycin, 100 mg/ml kanamycin, 400 mg/ml G418,
and with 0.3 mg/ml Tet (for inhibition of HBV replication) or
without any Tet (for induction of HBV replication). HepaRG
(Biopredic) cells (Gripon et al., 2002) were cultured in Williams
E medium containing HepaRG supplement medium. HBV 2.2.15
cells (Sells et al., 1987) were cultured in DMEM containing
10% FBS, 100 IU/ml penicillin, 100 mg/ml streptomycin, and 2 mM
L-glutamine.
Lentiviral transduction of cells
HepAD38 or HBV2.2.15 cells were transduced with lentiviral
vectors expressing a puromycin resistance gene as well as Spy
Cas9 and an sgRNA, as described above, at 85–90% conﬂuency after
growth in medium lacking Tet for 48 h, to ensure expression of
HBV mRNAs and DNA. Beginning at 48 h post-transduction, cells
were selected in 4 mg/ml puromycin (Life Technologies) for 10 days
to eliminate any non-transduced cells. Supernatant media and
cells were then harvested for ELISA and real-time PCR assays.
Control cells including non-transduced HepAD38 cells were
included as positive controls for HBV replication (in medium
lacking Tet) or virtual absence of HBV replication (in medium
containing Tet). Non-transduced HBV 2.2.15 cells were included as
a control in experiments where relevant.
HepaRG (Biopredic) cells were plated at a density of 8105
cells per well in a 6-well cell tissue culture plate (NUNC). Cells
were transduced 24 h later with the same Spy Cas9/sgRNA
expressing lentiviral vectors used above and selected with 5 mg/ml
puromycin. Cells were subsequently differentiated for 4 weeks in
HepaRG culture medium containing 2% DMSO (Sigma-Aldrich) for
HBV infection experiments.
HBV infection of Spy Cas9/sgRNA-expressing HepaRG stable cell line
HepaRG cells were infected with HBV particles produced from
HBV-producing 2.2.15 cells at an MOI of 30. HepaRG culture
conditions, differentiation and HBV infection have been described
previously (Hantz et al., 2009). One day post-infection, the cells
were washed three times with phosphate-buffered saline and
medium was replaced every two days during the experiment. To
evaluate the impact on HBV antigen expression and secretion,
supernatants were collected on day 4 and Day 17. HBV HBsAg and
HBeAg levels were measured using CLIA ELISA Kits (Autobio
Diagnostic), according to the manufacturer’s protocol. After the
removal of supernatant media, cells were incubated with CellTiter-
Glo One Solution (Promega) to measure cell viability.
To measure the effect of anti-HBV Cas9/sgRNA combinations on
viral production and cccDNA accumulation, from day 5 post-
infection onwards, some cultures were treated with entecavir
(Ark Pharma) at 1 mM and retreated every two days till harvest
on day 13.
On day 13 post-infection, HepaRG supernatant media were
collected and HBV HBsAg and HBeAg levels measured using CLIA
ELISA Kits (Autobio Diagnostic), according to the manufacturer’s
protocol. In addition, DNA isolation from the supernatant media
was performed using the MagNA Pure 96 DNA and Viral DNA
Small Volume Kit (Roche). To quantify HBV DNA, supernatant and
HBV plasmid (Genotype D) serial dilutions, as quantiﬁcation
standards, were used as templates for Taqman qPCR using an
HBV core gene speciﬁc primer. After removal of the supernatants,
the cells were lysed and total DNAwas extracted (Macherey-Nagel,
Tissue Kit). HBV DNA and cccDNAwere detected using speciﬁc PCR
primers and the LightCycler system (Roche), as described else-
where (Lucifora et al., 2014).
Quantiﬁcation of HBV DNA and cccDNA in HepAD38 cells
For HBV DNA quantiﬁcation in HepAD38 cells, a set of primers
for the HBV pre-S gene region was assessed according to a
published real-time PCR protocol (Pas et al., 2000), which yielded
an 89-bp product. For HBV cccDNA ampliﬁcation, we used TaqMan
primers previously shown (Chen et al., 2004) to speciﬁcally
amplify cccDNA using an AB7900 HT sequence detection system
(Applied Biosystems) or the Light Cycler 480 instrument (Roche).
Closely similar data (not shown) were also obtained using a
second set of previously described, HBV cccDNA-speciﬁc primers
(Malmstrom et al., 2012).
Nuclear extraction for cccDNA analysis
Trypsinized HepAD38 cells were collected by centrifugation,
washed with PBS and the supernatant medium discarded. We then
added 500 ml of hypotonic buffer (10 mM HEPES, 10 mM NaCl,
1.5 mM MgCl2, 0.5 mM DTT) to the cell pellets, along with
zirconium oxide beads (ZROB05, Next Advance), and the cytoplas-
mic membranes were disrupted using a Bullet Blender (Next
Advance), set at speed “4”, for 15 s. Nuclear pellets were then
collected by centrifugation at 2500 rpm for 5 min at 4 1C and total
nuclear DNA extracted following the protocol in the DNeasy Blood
& Tissue Kit (Qiagen).
Antiviral activity in HBV-CRISPR and HepAD38 systems
Four compounds were tested against the HepAD38 cells,
including lamivudine (3TC), tenofovir disoproxil fumarate (TDF),
entecavir (ETV), and the nucleocapsid assembly inhibitor hetero-
aryldihydropyrimidine (HAP-12). All the antivirals were synthe-
sized in our laboratories. HepAD38 cells were seeded at 50,000
cells/well in collagen-coated 96-well plates. Test compounds were
added to cells to a ﬁnal concentration ranging from 0.001 to
10 mM.
Real-time PCR for HBV DNA species in HepAD38
On day 7, total DNA was puriﬁed from supernatant using a
commercially available kit (DNeasy Blood & Tissue kit, Qiagen).
The HBV DNA was ampliﬁed in a real-time PCR assay using the AB
7900HT sequence detection system (Applied Biosystems) or the
LightCycler 480 (Roche) as described by Stuyver et al. (2002). All
samples were tested in duplicate. The concentration of compound
that inhibited HBV DNA replication by 50% (EC50) or 90% (EC90)
was determined by linear regression. HBV log viral reduction was
also determined.
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Cytotoxicity
Cell viability was checked using two assays at late time points.
For HepaRG, cell viability was monitored on Day 17 post-infection
using CellTiter-Glo One Solution (Promega), according to the
manufacturer’s protocol. No differences were observed between
controls and experimental samples (data not shown). For the
HepAD38 cells, Real-Time PCR for mitochondrial DNA [cytochrome
c oxidase subunit II (COXII)] and nuclear DNA (ribosomal DNA) was
performed. The mitochondrial DNA (MtDNA) and nuclear DNA
(ribosomal DNA, Applied Biosystems) were ampliﬁed in parallel in
a real-time PCR assay, and the amount of target mtDNA was
normalized to the amount of an endogenous control and was then
calculated relative to the untreated control. Again, no evidence of
cytotoxicity was observed (Table S1).
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